Eating disorders and illness burden in patients with bipolar spectrum disorders☆
To access this article, please choose from the options below
☆ Dr Marcus has served as a consultant to GlaxoSmithKline and Sanofi Aventis. Dr Fagiolini is on the advisory board for Pfizer Inc and Bristol-Meyers Squibb and is in the speaker bureau of Bristol-Meyers Squibb, Eli Lilly Italy, Pfizer Inc, and Shire.
PII: S0010-440X(07)00076-4
doi:10.1016/j.comppsych.2007.05.012
© 2007 Elsevier Inc. All rights reserved.
